Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia &/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines &/or vision loss, sensory symptoms
of pins & needles &/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms &/or unilateral sensory symptoms or at least 1 aura symptoms develop gradually over ≥5 minutes &/or different aura symptoms that occur in succession over ≥5 minutes.
New drug applications approved by US FDA as of 15 - 30 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals may
have occurred since the original approval date.
applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals
may have occurred since the original approval date.
Individuals who have failed between two and four preventive therapies for episodic migraine may derive benefit from a once-a-month dose of erenumab, according to results of the phase IIIb LIBERTY* study.
Migraine may potentially increase the risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter, according to a recent study. In addition, migraine may be a significant predictor for most cardiovascular diseases.
Fully monoclonal antibodies that target the calcitonin gene–related peptide (CGRP), particularly fremanezumab and erenumab, show potential in migraine prevention, significantly reducing the frequency of attacks in patients with chronic or episodic migraine, according to data from two phase III trials.
Osteopathic manipulative therapy (OMT) demonstrates therapeutic potential in patients with high-frequency migraine and comorbid mood disorders, with the improvements observed after four 45-minute OMT sessions, a study has shown.
A history of migraine headache is a predictor of increased risk of future cardiovascular (CV) events (cardiovascular death, nonfatal myocardial infarction, heart failure or stroke) on long-term follow-up among women being evaluated for ischaemic heart disease, according to a study. Moreover, this risk is mainly driven by a more than twofold rise in stroke risk.
Clinicians often face the dilemma of overinvestigating headaches caused by benign ailments and overlooking headaches that are manifestations of serious underlying conditions, despite advances in diagnostic techniques.
Transcutaneous occipital nerve stimulation (tONS) shows promise in the prevention of migraine, with infrequent and mild adverse events, according to a study. The intervention may be effective among patients who favour nonpharmacological treatment.
Adolescents appear to have disordered normal brain growth trajectories after initiating drinking, with or without co-use of marijuana, a recent study has found. Peak consumption in the past year and family history of alcoholism possibly contribute to abnormal cortical volume trajectories.